Evidence map›Paper›PMID 35565395›Full record

ReviewCancers2022

Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy.

Yang Zhou, Miao Li, Kuangyi Zhou, James Brown, Tasha Tsao, Xinjian Cen, Tiffany Husman, Aarushi Bajpai, Zachary Spencer Dunn, Lili Yang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Current Landscape of iPSC Haplobanks.Stem cell reviews and reports · 2024
    Review
  14. Article
  15. Review
  16. Article
  17. CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy.Clinical reviews in allergy & immunology · 2024
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yang ZhouDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Miao LiDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0003-0891-1143
Kuangyi ZhouDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0001-7904-9429
James BrownDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0003-2013-1609
Tasha TsaoDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Xinjian CenDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0002-1663-1347
Tiffany HusmanDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0003-0230-0878
Aarushi BajpaiDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0002-7302-4455
Zachary Spencer DunnDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0003-2500-6006
Lili YangDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
University of California, Los Angeles · USUniversity of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell-based immunotherapy, such as chimeric antigen receptor (CAR) T cell therapy, has revolutionized the treatment of hematological malignancies, especially in patients who are refractory to other therapies. However, there are critical obstacles that hinder the widespread clinical applications of current autologous therapies, such as high cost, challenging large-scale manufacturing, and inaccessibility to the therapy for lymphopenia patients. Therefore, it is in great demand to generate the universal off-the-shelf cell products with significant scalability. Human induced pluripotent stem cells (iPSCs) provide an "unlimited supply" for cell therapy because of their unique self-renewal properties and the capacity to be genetically engineered. iPSCs can be differentiated into different immune cells, such as T cells, natural killer (NK) cells, invariant natural killer T (iNKT) cells, gamma delta T (γδ T), mucosal-associated invariant T (MAIT) cells, and macrophages (Mφs). In this review, we describe iPSC-based allogeneic cell therapy, the different culture methods of generating iPSC-derived immune cells (e.g., iPSC-T, iPSC-NK, iPSC-iNKT, iPSC-γδT, iPSC-MAIT and iPSC-Mφ), as well as the recent advances in iPSC-T and iPSC-NK cell therapies, particularly in combinations with CAR-engineering. We also discuss the current challenges and the future perspectives in this field towards the foreseeable applications of iPSC-based immune therapy.

Indexed as

allogeneiccancerchimeric antigen receptor (CAR)gamma delta T (γδ T)immunotherapyinduced pluripotent stem cell (iPSC)invariant natural killer T (iNKT)macrophages (Mφs)mucosal-associated invariant T (MAIT)natural killer (NK)off-the-shelfreprogrammingT

Identifiers

PMID35565395
PMCPMC9100203
OpenAlexW4225253937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.